Effect of Camrelizumab Combined with Concurrent Chemoradiotherapy in the Treatment of Middle and Advanced Esophageal Squamous Cell Carcinoma/GU Guangfu，LI Caihong.//Medical Innovationof China，2025，22（18）：135-138

[Abstract] Objective： To explore the clinical effect of Camrelizumab combined with concurrent chemoradiotherapy in patients with middle and advanced esophageal squamous cellcarcinoma. Method： A total of 80 patients diagnosed with middleand advanced esophageal squamous cell carcinoma and admitted to the Second Affiliated Hospital of Xuzhou Medical University from May 2O2O to April2024 were selected.The patients were randomly divided intothe observation group and thecontrol group bythe computer digital table method，with 40 cases in each group. The control group received concurrent chemoradiotherapy，while the observation group was treated with Camrelizumabonthe basis ofthe control group.Theclinical eficacy，serum tumor markerlevels and the occurence of adverse reactions between the two groups were compared. Result： The disease control rate and objective effectiveratein theobservationgroup were both higherthan those inthecontrol group，the diferences were statisticallysignificant（ P lt;0.05）.After18 weeks of treatment，the levels of serum tumor markersin the observation group were all lower than those in the control group，the differences were statistically significant （ P- lt;0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups （ P gt;0.05）. Conclusion：For middle and advanced esophageal squamous cellcarcinoma patients，the addition of Camrelizumab treatment onthebasis of concuirent chemoradiotherapycanachieve satisfactory results，reducethe levels of serum tumormarkers，and hasarelatively high treatment safety.

[Key words]CamrelizumabConcurrent chemoradiotherapyEsophageal squamous cellcarcinoma

First-author'saddress： Radiotherapy Department， the Second Affiliated Hospital of Xuzhou Medical niversity，Xuzhou221006，China

doi：10.3969/j.issn.1674-4985.2025.18.031

食管癌也称为食道癌，是源自食管上皮组织的恶性肿瘤，主要病理类型为鳞癌。食管鳞癌的病因包括不合理饮食、肥胖、癌前病变等，患者发病初期无明显症状，疾病进展至中晚期表现为吞咽困难、疼痛、身体消瘦、呕血及便血等症状。食管鳞癌起病隐匿，大部分患者确诊时已经处于疾病中晚期，手术时机丧失，临床多通过同步放化疗方案杀灭肿瘤，控制病情进展，但治疗期间不良反应发生率较高，患者耐受度偏低，治疗及预后效果不佳[2。免疫治疗为临床治疗中晚期食管鳞癌的全新方案，卡瑞利珠单抗属于人源程序性死亡受体1（PD-1）抑制剂，用药后可结合PD-1，有效解除免疫抑制，有效抗肿瘤，并可辅助提升同步放化疗的临床疗效[3。基于此，本研究选取80例中晚期食管癌患者，评估在开展同步放化疗治疗的基础上增加卡瑞丽珠单抗治疗实际效果。

1资料与方法

1.1一般资料

选择2020年5月一2024年4月徐州医科大学第二附属医院接收明确诊断为中晚期食管鳞癌的80例患者。纳入标准：（1）采集病理组织进行检查结论为食管鳞癌。（2）预计生存时间不低于3个月。排除标准：（1）合并自身免疫性疾病。（2）合并其他部位恶性肿瘤。（3）入组前接受治疗干预。采用随机对照分析方案，通过电脑数字表法将患者随机分为观察组与对照组，各40例。研究具体事项报请徐州医科大学第二附属医院医学伦理委员会核准，患者知悉研究的具体内容，并签署知情同意书。

1.2 方法

对照组接受同步放化疗治疗，方案如下：（1）放疗。……